RBC Capital Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH)
In a report released on April 13, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Zimmer Biomet Holdings, with a price target of $101.00. The company’s shares closed yesterday at $95.34.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Medtronic, and Becton Dickinson. According to TipRanks, Singh Chadha has an average return of 0.0% and a 45.23% success rate on recommended stocks.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $98.92.
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year. Last month, Lori Winkler, the SVP and CHRO of ZBH sold 2,650.00 shares for a total of $250,849.00.
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Nike downgraded, Starbucks upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Market Perform at Leerink
- William Blair med tech analyst holds an analyst/industry conference call
- Zimmer Biomet names new Chief Science, Technology and Medical Affairs Officer
- Zimmer Biomet’s RibFix Titan Study: What Chest Wall Data Could Mean for ZBH Investors
